Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273116 | 0.79 | CYP1A2 (0.44) | S1PR1CYP1A2CYP2C9CYP2C19EPHX2 | |
| SCHEMBL4070829 | 0.77 | EPHX2 (0.40) | EPHX2PPARGALDH1A1MAPK1 | |
| SCHEMBL274988 | 0.74 | AR (0.51) | S1PR1CYP1A2CYP2C9CYP2C19EPHX2 | |
| SCHEMBL29999042 | 0.74 | AR (0.51) | S1PR1CYP1A2CYP2C9CYP2C19EPHX2 | |
| SCHEMBL28023584 | 0.69 | S1PR1 (0.49) | S1PR1CYP1A2CYP2C9CYP2C19EPHX2 | |
| SCHEMBL28385389 | 0.68 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19EPHX2NR1H4 | |
| SCHEMBL28385415 | 0.68 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19EPHX2NR1H4 | |
| SCHEMBL4936391 | 0.68 | CYP1A2 (0.47) | S1PR1CYP1A2CYP2C9CYP2C19EPHX2 | |
| SCHEMBL3182950 | 0.68 | RET (0.63) | CYP3A4MAPK1HTT | |
| SCHEMBL4937157 | 0.67 | KIT (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2371822-A1 | Heterobicyclic carboxamides as inhibitors for kinases | Novartis AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074125-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | S1PR1 1419/4885CYP1A2 3937/4885CYP2C9 3712/4885 |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | S1PR1 2415/4885CYP1A2 1711/4885CYP2C9 717/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | S1PR1 3357/4885CYP1A2 3257/4885CYP2C9 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.